Related Experiment Video

Updated: Jun 19, 2026

Establishment and Characterization of Three Afatinib-resistant Lung Adenocarcinoma PC-9 Cell Lines Developed with Increasing Doses of Afatinib
09:38

Establishment and Characterization of Three Afatinib-resistant Lung Adenocarcinoma PC-9 Cell Lines Developed with Increasing Doses of Afatinib

Published on: June 26, 2019

New targeted therapies for non-small-cell lung cancer: a focus on the epidermal growth factor receptor

Jeffrey Crawford1

  • 1From the Department of Clinical Research, Duke University Medical Center, Duke Comprehensive Cancer Center, Durham, NC 27710, USA. crawf006@mc.duke.edu

Journal of the National Comprehensive Cancer Network : JNCCN
|October 3, 2009
PubMed

Insights

New therapies targeting the epidermal growth factor receptor (EGFR) show promise for non-small-cell lung cancer (NSCLC). EGFR inhibitors offer clinical benefit in advanced NSCLC and are being explored in earlier stages.

Area of Science:

  • Oncology
  • Molecular Biology
  • Pharmacology

Background:

  • Non-small-cell lung cancer (NSCLC) treatment has seen modest gains.
  • Novel therapeutic strategies targeting cancer cell proliferation are needed.
  • Epidermal growth factor receptor (EGFR) is a key target in NSCLC.

Purpose of the Study:

  • To review advances in EGFR-targeted therapies for NSCLC.
  • To discuss the role of EGFR inhibition in preclinical and clinical settings.
  • To highlight ongoing research integrating EGFR inhibitors with standard treatments.

Main Methods:

  • Review of preclinical studies on EGFR inhibition.
  • Analysis of Phase II clinical trials of EGFR inhibitors in advanced NSCLC.
  • Discussion of ongoing studies in earlier stage NSCLC and chemoprevention.

Main Results:

  • EGFR inhibition demonstrated growth inhibition and tumor regression in preclinical models.
  • Phase II trials showed clear clinical benefit in advanced NSCLC patients progressing after chemotherapy.
  • EGFR tyrosine kinase inhibitors are the most studied agents in NSCLC.

Conclusions:

  • EGFR-targeted therapies, particularly tyrosine kinase inhibitors, represent a promising strategy for NSCLC.
  • Further understanding of EGFR biology is crucial for optimizing these novel agents.
  • Ongoing research is exploring the integration of EGFR inhibitors with chemotherapy and radiation for improved NSCLC outcomes.

More Related Videos

Ultra-Fast Amplicon-Based Next-Generation Sequencing in Non-Squamous Non-Small Cell Lung Cancer07:59

Ultra-Fast Amplicon-Based Next-Generation Sequencing in Non-Squamous Non-Small Cell Lung Cancer

Published on: September 8, 2023

Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells In Vitro with a 2-step Dose-escalation Procedure09:38

Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells In Vitro with a 2-step Dose-escalation Procedure

Published on: August 11, 2017

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers01:26

Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers

Receptor tyrosine kinase inhibitors (TKIs) and calcium channel blockers (CCBs) are two critical categories of drugs employed in the treatment of pulmonary artery hypertension (PAH). PAH is a disease that causes high blood pressure in the pulmonary arteries, resulting in chest pain, fatigue, and shortness of breath.
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
Transducer Mechanism: Enzyme-Linked Receptors01:27

Transducer Mechanism: Enzyme-Linked Receptors

Enzyme-linked receptors are cell-surface receptors acting as an enzyme or associating with an enzyme intracellularly. They make excellent drug targets. Drugs can bind to the extracellular ligand-binding domain or directly affect their enzymatic domain and alter their activity.
Major types that are helpful drug targets include:
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...